探究莫沙比利联合瑞巴派特治疗慢性萎缩性胃炎的安全性

To Explore the Security of Mosapride Joint Rebamipide in Treatment of Chronic Atrophic Gastritis

目的探究莫沙比利联合瑞吧派特治疗慢性萎缩性胃炎的临床治疗效果和安全性,为临床上治疗该病提供可靠的理论依据。方法对我院接受治疗的64例慢性萎缩性胃炎患者的临床资料进行分析,并按照随机原则分为观察组和对照组,对照组患者给予单纯莫沙比利治疗,观察组患者给予莫沙比利与瑞巴派特联合治疗,分析和比较两组患者的治疗总有效率和幽门杆菌根除率。结果观察组患者的治疗总有效率为90.63%,高于对照组(P<0.05);观察组的幽门杆菌根除率为87.5%,高于对照组(P<0.05)。结论在临床治疗慢性萎缩性胃炎中应用莫沙比利联合瑞巴派特能取得理想的治疗效果,并且其幽门杆菌根除率优于单独使用莫沙比利。

Objective To explore joint Swiss Bar Mosapride Pat treatment of chronic atrophic gastritis of clinical efficacy and safety for the clinical treatment of the disease to provide a reliable theoretical basis. Methods The clinical data in our hospital treated 64 cases of chronic atrophic gastritis patients were analyzed, and the principle divided into observation group and control group according to randomized control patients administered alone mosapride treatment, the observation group were given mosapride and rebamipide treatment, analysis and comparison of the two groups of patients with total effective and Helicobacter pylori eradication rates. Results The total effective rate of the treatment of patients 90.63%, significantly higher （P〈0.05）, observation group of H. pylori eradication rate was 87.5%, significantly higher （P〉0.05）. Conclusion The clinical treatment of chronic atrophic gastritis in treatment effect Mosapride joint rebamipide made good, and the H. pylori eradication rate was significantly better than alone mosapride.